Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionEmpirical Finance, LLC
Latest Disclosed Ownership8,694 shares
Latest Disclosed Value $ 3,882,219
Empirical Finance, LLC reports 0.20% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 14, 2026 - Empirical Finance, LLC filed a 13F-HR/A form disclosing ownership of 8,694 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $3,882,219 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 8,711 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -0.20% during the quarter. The current value of the position is $3,840,488 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 8,694 -17 -0.20 3,882 -1.70 0.1824
2026-05-14 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,694 -17 3,882 0.1824
2026-02-12 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,711 -782 -8.24 3,949 6.24 0.1884
2025-11-13 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9,493 487 5.41 3,718 -7.28 0.1770
2025-08-11 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9,006 60 0.67 4,009 -7.56 0.2099
2025-05-07 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,946 133 1.51 4,337 22.24 0.2619
2025-01-28 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,813 -103 -1.16 3,549 -14.42 0.2053
2024-11-06 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,916 190 2.18 4,147 1.37 0.2418
2024-07-30 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,726 -606 -6.49 4,090 4.87 0.2555
2024-05-06 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 9,332 314 3.48 3,901 6.30 0.2394
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 9,018 48 0.54 3,669 17.63 0.2559
2023-11-02 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,970 865 10.67 3,119 9.36 0.2291
2023-07-27 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,105 938 13.09 2,852 26.31 0.2209
2023-04-05 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,167 345 5.06 2,258 14.62 0.2115
2023-02-21 2022-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 6,822 545 8.68 1,970 8.42 0.2040
2023-01-24 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,822 545 2 0.2040
2022-11-04 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,277 1,032 19.68 1,817 22.94 0.2155
2022-08-01 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,245 273 5.49 1,478 13.87 0.1884
2022-04-21 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,972 530 11.93 1,298 33.13 0.1454
2022-02-04 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,442 1,179 36.13 975 64.70 0.1151
2021-11-12 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,263 186 6.04 592 -4.52 0.0892
2021-08-10 2021-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 3,077 428 16.16 620 -0.96 0.1011
2021-08-04 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,649 0 626 0.1101
2021-05-13 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,649 0 0.00 626 0.00 0.1101
2021-02-02 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,649 466 21.35 626 5.39 0.1101
2020-10-28 2020-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 2,183 485 28.56 594 20.49 0.1273
2020-07-20 2020-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 1,698 216 14.57 493 39.66 0.1261
2020-04-16 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,482 533 56.16 353 69.71 0.1097
2020-01-27 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 949 949 208 0.0506
2017-05-11 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -104 -100.00 0 -100.00
2017-02-13 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 104 104 8 0.0054
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.